Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in COVID-19 ARDS
NCT04482621Phase 2Suspended
- Sponsor
- Johns Hopkins University
- Start
- Sep 2020
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of decitabine in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS), sponsored by Johns Hopkins University. Started Sep 2020; status: suspended.
02
Drugs
decitabine
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04482621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482621.